US 12,331,048 B2
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
Stéphane Dorich, Pointe-Claire (CA); and Stéphane Ciblat, Montreal (CA)
Assigned to Ventus Therapeutics U.S., Inc., Waltham, MA (US)
Filed by Ventus Therapeutics U.S., Inc., Waltham, MA (US)
Filed on Mar. 27, 2023, as Appl. No. 18/190,920.
Application 18/190,920 is a continuation of application No. PCT/US2023/064967, filed on Mar. 24, 2023.
Claims priority of provisional application 63/443,874, filed on Feb. 7, 2023.
Claims priority of provisional application 63/420,930, filed on Oct. 31, 2022.
Prior Publication US 2024/0174661 A1, May 30, 2024
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) 18 Claims
 
1. A compound of Formula (VI-b1):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or isotopically labeled compound thereof, wherein:
R3 is C1-C6 alkyl or C1-C6 alkoxy;
X is H, halogen, or C1-6 alkyl; and
R4 is H;
wherein each instance of alkyl or alk—is independently substituted with 0, 1, 2, or 3 halogen atoms.